Biomarkers Market Size to Estimate USD 366.6 Billion by 2034

Biomarkers Market Companies, Advances and Trends

The biomarkers market size was estimated at US$ 82.35 billion in 2023 and is projected to grow to US$ 366.6 billion by 2034, rising at a compound annual growth rate (CAGR) of 14.54% from 2024 to 2034. The rising incidences of chronic disorders, growing research and development, and increasing investments drive the market.

Unlock Infinite Advantages: Subscribe to Annual Membership

Biomarkers Market: Tracing the Disease

Biomarkers or biological markers are molecules found in blood, body fluids, or tissues that explain what is happening in a cell or organism. They are used to perform clinical assessments and monitor and predict health states in individuals. For instance, high levels of lead in the bloodstream may indicate a need to test for nervous system and cognitive disorders, especially in children. Biomarkers play a crucial role in determining relationships between environmental exposures, human biology, and disease. A biomarker can also act as a diagnostic measure that examines the organ function or other aspects of health when introduced into an organism. Biomarkers can also aid in disease prognosis by providing information about the patient's overall outcome, regardless of any treatment or therapeutic intervention.

The rising incidence and prevalence of chronic disorders potentiates the demand for finding the root cause of the disease and aiding in novel drug discovery and development. The growing research and development boost biomarkers research. The market is also driven by increasing investments from both government and private organizations, and collaborations augment the market.

Biomarkers Market Trends

• In October 2024, SanboxAQ, an AI and quantum technology company, announced the collaboration with Sanofi to locate biomarkers using large quantitative models (LQMs) to gain a better understanding of human biology. The collaboration was made to support scientists’ ability to promote trust throughout investigational medicines and clinical development.
• In October 2024, MEDiC Life Sciences announced the collaboration with Hanmi Pharmaceutical. The collaboration was made to use MEDiC’s MCAT platform to identify cancer biomarkers for one of Hanmi’s clinical assets.
• In August 2024, the University of Nevada, Las Vegas, received a $3.2 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to develop a biomarker observatory to diagnose and monitor Alzheimer’s disease.

Artificial Intelligence: Opportunity for the Biomarkers Market

Artificial intelligence (AI) revolutionizes research and development activities, streamlining the workflow. Biomarkers are an essential part of routine clinical practice, complementing clinical examination and physician expertise to provide accurate disease diagnosis, prediction of complications, personalized treatment guidance, and prognosis. The advent of advanced technologies simplifies the discovery of biomarkers using larger data sets, resulting in improved analysis. Additionally, digital biomarkers offer powerful interpretations of a patient’s digital measurements and correlated medical conditions. Sensors, wearables, and digital platforms are some examples of digital biomarkers that can capture and analyze an array of physiological, behavioral, and environmental data. These measurements are provided by a digital ecosystem that gives people and their healthcare professionals dynamic and individualized health insights. Hence, such advanced technologies can deeply transform healthcare by driving innovations in disease prevention, diagnostics, treatment, and monitoring.

Disease Heterogeneity and Complexity Hinder the Biomarkers Market

The major challenge of the market is disease heterogeneity. A biomarker may be specific to certain types of disease and even within the same type of disease, but it can vary between patients. This limits the clinical applications of biomarkers. Another major challenge is the disease complexity. Biomarkers may not give a complete understanding of the disease due to the full complexity of the disease.

Regional Insights

Favorable Government Policies Dominated North America

North America held the largest share of the biomarkers market in 2023. State-of-the-art research and development, favorable government policies, rising incidences of chronic disorders, and the presence of key players drive the market. The US FDA encourages the integration of biomarkers in medical product development and approval, thereby helping to speed the development of promising new therapeutics. The Canadian Health Measures Survey (CHMS) is an ongoing national human biomonitoring survey led by Statistics Canada in collaboration with Health Canada and the Public Health Agency of Canada. The market is also driven by novel drug discovery research in the region.

Rising Incidences of Chronic Disorders Promote Asia-Pacific

Asia-Pacific is projected to host the fastest-growing biomarkers market in the coming years. The rising incidence and prevalence of chronic disorders, growing research and development, and increasing investments & collaborations drive the market. The rising incidence of cancer and immunological and neurological disorders potentiates the demand for biomarkers in disease diagnosis and novel drug discovery. It is estimated that China has more than 15 million people over 60 years old living with dementia. India reported 8.8 million cases of dementia in people 60 years or older. At the same time, Japan accounted for approximately 3.9 million cases in 2023. The huge demand for biomarkers research is due to the increasing geriatric population, rapid urbanization, and changing demographics in the region.

Segmental Insights

By type, the safety biomarkers segment led the global biomarkers market in 2023. A safety biomarker indicates the possibility, existence, or degree of toxicity as an unfavorable impact that is tested either before or after exposure to a medicinal product or environmental contaminant. The demand is attributed to their implementation in early clinical trials, which plays a key role in decision-making and facilitates the progression of promising therapeutics from preclinical to clinical development.

The efficacy biomarkers segment is expected to grow at the fastest rate in the market during the forecast period. Efficacy biomarkers are indicators of a drug’s therapeutic effects. They refer to early events in disease progression, toxic changes, or pharmacological events.

By disease, the cancer segment held a dominant presence in the biomarkers market in 2023. The rising incidences of cancer, cancer complexity, rapid mutations, and demand for personalized medicines augment the segment’s growth. Biomarkers can help in cancer diagnosis, prognosis, or likelihood of disease recurrence independent of treatment.

The neurological diseases segment is anticipated to grow at a significant CAGR in the market during the studied years. The rising geriatric population and increasing incidence and prevalence of neurological disorders like Alzheimer’s disease and Parkinson’s disease drive the segment growth.

By application, the drug discovery & development segment registered its dominance over the global biomarkers market in 2023. Since biomarkers give a deeper understanding of the disease pathway, they assist in novel drug discovery and development. The increasing awareness and investments & collaborations promote the segment’s growth.

Top Companies in the Biomarkers Market

• Abbott
• Alto Neuroscience, Inc.
• Hanmi Pharmaceutical
• Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Labcorp Biopharma
• MEDiC Life Sciences
• Qiagen
• Regeneron
• Sanofi
• Siemens Healthineers
• Thermo Fisher Scientific

Latest Announcements by Industry Leaders

Rinol Alaj, Senior Director of Digital Health Technologies at Regeneron, commented that many companies are working independently on building digital biomarkers. Hence, the company organized the Digital Biomarkers Summit in May 2024, which could be a terrific opportunity to bring the industry together and create a mechanism of collaboration to help accelerate overall digital biomarker adoption. He also explained that researching digital biomarkers requires change management, innovative thinking/frameworks, and novel ways of problem-solving.

Recent Developments in the Biomarkers Market

• In October 2024, researchers from the Walter and Eliza Hall Institute investigated the role of extracellular vesicles as biomarkers in cancer treatment. They found that there were abnormally high levels of extracellular vesicles in the blood of mice with leukemia.
• In October 2024, researchers from Nationwide Children’s identified a potential biomarker to examine the presence of single ventricle heart disease (SVHD) in a fetus based on a maternal blood test. They found elevated levels of cell-free miRNAs in the blood of mothers carrying a baby with an SVHD.

Segments Covered in the Report

By Type

• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers

By Disease

• Cancer
• Neurological Diseases
• Immunological Diseases
• Cardiovascular Diseases
• Others

By Application

• Drug Discovery & Development
• Personalized Medicines
• Diagnostics
• Others

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait